Company Registration No. 11885096 (England and Wales)
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Annual report and financial statements
for the year ended 31 December 2024
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Company information
Directors
Hannah Haigh
Chris Haynes
(Appointed 30 April 2025)
Secretary
Chris Haynes
Company number
11885096
Registered office
Irongate House
30 Dukes Place
London
EC3A 7LP
Independent auditor
Saffery LLP
71 Queen Victoria Street
London
EC4V 4BE
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Contents
Page
Directors' report
1 - 2
Independent auditor's report
3 - 5
Income statement
6
Statement of financial position
7
Statement of changes in equity
8
Notes to the financial statements
9 - 15
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Directors' report
For the year ended 31 December 2024
1
The directors present their annual report and financial statements for the year ended 31 December 2024.
Principal activities
The principal activity of the company continued to be that of a holding company.
Results and dividends
The results for the year are set out on page 6.
No ordinary dividends were paid (2023: £nil). The directors do not recommend payment of a final dividend (2023: £nil).
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
Hannah Haigh
Stephen Herniman
(Resigned 30 April 2025)
Chris Haynes
(Appointed 30 April 2025)
Auditor
Saffery LLP have expressed their willingness to continue in office.
Statement of directors' responsibilities
The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 101 "Reduced Disclosure Framework" (FRS 101) (United Kingdom Accounting Standards and applicable law).
Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
state whether applicable United Kingdom Accounting Standards, including FRS 101, have been followed, subject to any material departures disclosed and explained in the financial statements,
notify the Company's shareholders in writing about the use of disclosure exemptions, if any, of FRS 101, used in the preparation of the financial statements; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Directors' report (continued)
For the year ended 31 December 2024
2
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.
Safeguarding
The directors are responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Small companies exemption
This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
On behalf of the board
Hannah Haigh
Director
30 July 2025
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Independent auditor's report
To the members of Meet Life Sciences Group Limited (Formerly Meet Group Limited)
3
Opinion
We have audited the financial statements of Meet Life Sciences Group Limited (Formerly Meet Group Limited) (the 'company') for the year ended 31 December 2024 which comprise the income statement, the statement of financial position, the statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 101, "Reduced Disclosure Framework" (FRS 101).
In our opinion, the financial statements:
give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its loss for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice including FRS 101; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the directors' report has been prepared in accordance with applicable legal requirements.
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Independent auditor's report (continued)
To the members of Meet Life Sciences Group Limited (Formerly Meet Group Limited)
4
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement set out on page 1, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud are detailed below.
Identifying and assessing risks related to irregularities:
We assessed the susceptibility of the company’s financial statements to material misstatement and how fraud might occur, including through discussions with the directors, discussions within our audit team planning meeting, updating our record of internal controls and ensuring these controls operated as intended. We evaluated possible incentives and opportunities for fraudulent manipulation of the financial statements. We identified laws and regulations that are of significance in the context of the company by discussions with directors and updating our understanding of the sector in which the company operates.
Laws and regulations of direct significance in the context of the company include The Companies Act 2006 and UK Tax legislation.
Audit response to risks identified
We considered the extent of compliance with these laws and regulations as part of our audit procedures on the related financial statement items including a review of financial statement disclosures. We reviewed the company's records of breaches of laws and regulations, minutes of meetings and correspondence with relevant authorities to identify potential material misstatements arising. We discussed the company's policies and procedures for compliance with laws and regulations with members of management responsible for compliance.
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Independent auditor's report (continued)
To the members of Meet Life Sciences Group Limited (Formerly Meet Group Limited)
5
During the planning meeting with the audit team, the engagement partner drew attention to the key areas which might involve non-compliance with laws and regulations or fraud. We enquired of management whether they were aware of any instances of non-compliance with laws and regulations or knowledge of any actual, suspected or alleged fraud. We addressed the risk of fraud through management override of controls by testing the appropriateness of journal entries and identifying any significant transactions that were unusual or outside the normal course of business. We assessed whether judgements made in making accounting estimates gave rise to a possible indication of management bias. At the completion stage of the audit, the engagement partner’s review included ensuring that the team had approached their work with appropriate professional scepticism and thus the capacity to identify non-compliance with laws and regulations and fraud.
There are inherent limitations in the audit procedures described above and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.
A further description of our responsibilities is available on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
Richard Collis (Senior Statutory Auditor)
For and on behalf of Saffery LLP
30 July 2025
Statutory Auditors
71 Queen Victoria Street
London
EC4V 4BE
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Income statement
For the year ended 31 December 2024
6
2024
2023
Notes
£
£
Administrative expenses
(22,288)
(Loss)/profit before taxation
(22,288)
Tax on (loss)/profit
(Loss)/profit and total comprehensive income for the financial year
(22,288)
The financial statements have been prepared on the basis that all operations are continuing operations. The notes on pages 9 to 15 form an integral part of the financial statements.
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Statement of financial position
As at 31 December 2024
7
2024
2023
Notes
£
£
£
£
Non-current assets
Investments
3
489,402
511,690
Current assets
Trade and other receivables
5
423,476
423,476
Current liabilities
(22,288)
(22,288)
Net current assets
401,188
401,188
Net assets
890,590
912,878
Equity
Called up share capital
7
10,444
10,444
Retained earnings
880,146
902,434
Total equity
890,590
912,878
The financial statements have been prepared on the basis that all operations are continuing operations. The notes on pages 9 to 15 form an integral part of the financial statements.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the board of directors and authorised for issue on 30 July 2025 and are signed on its behalf by:
Hannah Haigh
Director
Company registration number 11885096 (England and Wales)
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Statement of changes in equity
For the year ended 31 December 2024
8
Share capital
Retained earnings
Total
£
£
£
Balance at 1 January and 31 December 2023
10,444
902,434
912,878
Year ended 31 December 2024:
Profit and total comprehensive income
-
(22,288)
(22,288)
Balance at 31 December 2024
10,444
880,146
890,590
The financial statements have been prepared on the basis that all operations are continuing operations. The notes on pages 9 to 15 form an integral part of the financial statements.
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Notes to the financial statements
For the year ended 31 December 2024
9
1
Accounting policies
Company information
Meet Life Sciences Group Limited (Formerly Meet Group Limited) is a private company limited by shares incorporated in England and Wales. The registered office is Irongate House, 30 Dukes Place, London, EC3A 7LP.
1.1
Accounting convention
The financial statements have been prepared in accordance with Financial Reporting Standard 101 "Reduced Disclosure Framework" (FRS 101) and in accordance with those parts of the Companies Act 2006 applicable to companies reporting under IFRS.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
As permitted by FRS 101, the company has taken advantage of the following disclosure exemptions from the requirements of IFRS:
inclusion of an explicit and unreserved statement of compliance with IFRS;
presentation of a statement of cash flows and related notes;
disclosure of the objectives, policies and processes for managing capital;
disclosure of key management personnel compensation;
disclosure of the categories of financial instrument and the nature and extent of risks arising on these financial instruments;
the effect of financial instruments on the statement of comprehensive income;
disclosure of the future impact of new International Financial Reporting Standards in issue but not yet effective at the reporting date;
comparative narrative information;
related party disclosures for transactions with the parent or wholly owned members of the group.
Where required, equivalent disclosures are given in the group accounts of Project Panda Topco Limited as ultimate parent company. The group accounts of Project Panda Topco Limited are available to the public and can be obtained as set out in note 10.
The company has taken advantage of the exemption under section 400 of the Companies Act 2006 not to prepare consolidated accounts. The financial statements present information about the company as an individual entity and not about its group.
Meet Life Sciences Group Limited (Formerly Meet Group Limited) is a wholly owned subsidiary of Project Panda Topco Limited and the results of Meet Life Sciences Group Limited (Formerly Meet Group Limited) are included in the consolidated financial statements of Project Panda Topco Limited which are available from Irongate House, 30 Dukes Place, London, EC3A 7LP.
1.2
Going concern
The directors have at the time of approving the financial statements, a reasonable expectation that the truecompany has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Cash and cash equivalents
Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Notes to the financial statements (continued)
For the year ended 31 December 2024
1
Accounting policies (continued)
10
1.4
Financial assets
Financial assets are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument. Financial assets are classified into specified categories, depending on the nature and purpose of the financial assets.
The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Company’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient are measured at the transaction price as disclosed in the section 'Revenue recognition'.
Financial assets held at amortised cost
For purposes of subsequent measurement, financial assets are classified in two categories:
The Company's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows, which will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets at amortised cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognised, modified or impaired. In order for a financial asset to be classified and measured at amortised cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. All other assets are classified and measured at fair value through profit or loss.
All financial assets, other than cash and cash equivalents and derivatives, are classified and measured at 'amortised cost'. The amortised cost of a financial asset is measured at initial recognition minus the principal repayments, plus the cumulative amortisation using the effective interest rate method of any difference between that initial amount and the maturity amount, adjusted for any loss allowance. The gross carrying amount of a financial asset is the amortised cost of a financial asset before adjusting for any loss allowance. Interest income is recognised using the effective interest rate method for financial assets subsequently measured at amortised cost. For financial assets other than purchased or originated credit-impaired financial assets, interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired.
Impairment of financial assets
Where there has not been a significant increase in exposure to credit risk since initial recognition, a lifetime credit loss allowance is estimated. This represents a portion of the asset's lifetime expected credit losses that is attributable to a default event. Where a financial asset has become credit impaired or where it is determined that credit risk has increased significantly, the loss allowance is based on the asset's lifetime expected credit losses. The amount of the expected credit loss recognised is adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables.
For trade receivables, the Company applies a simplified approach in calculating expected credit losses ("ECLs"). Therefore, the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. This is further enhanced with specific provisions where this is deemed appropriate by management.
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Notes to the financial statements (continued)
For the year ended 31 December 2024
1
Accounting policies (continued)
11
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership to another entity.
Trade and other receivables
Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 to 90 days.
1.5
Financial liabilities
The company recognises financial debt when the company becomes a party to the contractual provisions of the instruments. Financial liabilities are classified as either 'financial liabilities at fair value through profit or loss' or 'other financial liabilities'.
Other financial liabilities
Other financial liabilities, including borrowings, trade payables and other short-term monetary liabilities, are initially measured at fair value net of transaction costs directly attributable to the issuance of the financial liability. They are subsequently measured at amortised cost using the effective interest method. For the purposes of each financial liability, interest expense includes initial transaction costs and any premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding.
Derecognition of financial liabilities
Financial liabilities are derecognised when, and only when, the company’s obligations are discharged, cancelled, or they expire.
Trade and other payables
Trade and other payables represent liabilities for services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.
1.6
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.7
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Notes to the financial statements (continued)
For the year ended 31 December 2024
1
Accounting policies (continued)
12
Deferred tax
Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to 'other comprehensive income', in which case the deferred tax is also dealt with in 'other comprehensive income'. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
Total
2
2
During the current year, statutory directors of the company were remunerated through another group entity and as a result no remuneration was recognised in Meet Life Sciences Group Limited.
3
Investments
Current
Non-current
2024
2023
2024
2023
£
£
£
£
Investments in subsidiaries
-
-
489,402
511,690
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Notes to the financial statements (continued)
For the year ended 31 December 2024
3
Investments (continued)
13
Movements in non-current investments
Shares in subsidiaries
£
Cost or valuation
At 1 January 2024 & 31 December 2024
511,690
Impairment
At 1 January 2024
-
Impairment losses
(22,288)
At 31 December 2024
(22,288)
Carrying amount
At 31 December 2024
489,402
At 31 December 2023
511,690
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Notes to the financial statements (continued)
For the year ended 31 December 2024
14
4
Subsidiaries
Details of the company's subsidiaries at 31 December 2024 are as follows:
Name of undertaking
Registered office
Class of
shares held
% Held
Direct
Meet Life Sciences Limited
Irongate House, 30 Dukes Place, London, EC3A 7LP
Ordinary
100
Meet Life Sciences Inc.
140 Broadway, New York, NY 10005
Ordinary
100
Meet Personalberatung GmbH
Trogerstraße 23, 81675, Munchen
Ordinary
100
5
Trade and other receivables
2024
2023
£
£
Amounts owed by fellow group undertakings
421,267
421,267
Other receivables
2,209
2,209
423,476
423,476
Amounts owed by fellow group undertakings are unsecured, interest-free and repayable on demand.
6
Trade and other payables
2024
2023
£
£
Amounts owed to fellow group undertakings
22,288
22,288
Amounts owed to fellow group undertakings are unsecured, interest-free and repayable on demand.
7
Share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary participating shares of £1 each
9,028
9,028
9,028
9,028
Ordinary non-participating shares of £1 each
456
456
456
456
A Shares of £1 each
576
576
576
576
B Shares of £1 each
384
384
384
384
10,444
10,444
10,444
10,444
Meet Life Sciences Group Limited (Formerly Meet Group Limited)
Notes to the financial statements (continued)
For the year ended 31 December 2024
7
Share capital (continued)
15
Ordinary participating shares have full voting, dividend and capital distribution rights attached.
Ordinary non-participating shares have full rights to return of capital, but no rights as to voting or dividends attached.
Class A and B shares have rights to return of capital in accordance with the articles of association, but no rights as to voting or dividends attached.
8
Events after the reporting date
The directors have assessed events occurring after the reporting date up to the date of approval and concluded that there were no events requiring adjustment to or disclosure in the financial statements.
9
Related party transactions
FRS 101 exempts preparers from the requirements of para. 17 and 18A of IAS 24, meaning that FRS 101 accounts do not disclose related party transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned within the group. All transactions are with wholly owned companies within the group.
10
Controlling party
The immediate parent of the company is Project Panda Bidco Limited. The ultimate parent company is Project Panda Topco Limited, The directors consider their to be no one ultimate controlling party. The consolidated financial statements of Project Panda Topco Limited are available from its registered office, Irongate House, 30 Dukes Place, London, EC3A 7LP.
2024-12-312024-01-01Hannah HaighStephen HernimanChris HaynesChris HaynesfalsefalseCCH SoftwareiXBRL Review & Tag 2024.2118850962024-01-012024-12-3111885096bus:Director12024-01-012024-12-3111885096bus:CompanySecretaryDirector12024-01-012024-12-3111885096bus:CompanySecretary12024-01-012024-12-3111885096bus:Director22024-01-012024-12-3111885096bus:Director32024-01-012024-12-3111885096bus:RegisteredOffice2024-01-012024-12-31118850962024-12-31118850962023-01-012023-12-3111885096core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3111885096core:RetainedEarningsAccumulatedLosses2023-01-012023-12-31118850962023-12-3111885096core:ShareCapital2024-12-3111885096core:ShareCapital2023-12-3111885096core:RetainedEarningsAccumulatedLosses2024-12-3111885096core:RetainedEarningsAccumulatedLosses2023-12-31118850962022-12-3111885096core:ShareCapitalOrdinaryShares2024-12-3111885096core:ShareCapitalOrdinaryShares2023-12-3111885096core:Held-to-maturityFinancialAssets2024-01-012024-12-3111885096core:Subsidiary12024-01-012024-12-3111885096core:Subsidiary22024-01-012024-12-3111885096core:Subsidiary32024-01-012024-12-3111885096core:CurrentFinancialInstruments2024-12-3111885096core:CurrentFinancialInstruments2023-12-3111885096bus:PrivateLimitedCompanyLtd2024-01-012024-12-3111885096bus:FRS1012024-01-012024-12-3111885096bus:Audited2024-01-012024-12-3111885096bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP